Diala Ezzeddine

Diala Ezzeddine

Company: Xios Therapeutics

Job title: Chief Executive Officer


Enabling Therapeutic Degradation of Undruggable Targets 11:30 am

DNA-encoded library (DEL) technology is uniquely enabling for development of the next generation of PROTAC therapeutics: DEL can yield ligands with the desired attributes for compelling but undruggable targets DEL is equally powerful at generating adequate ligands for recruiting E3 ligases via PROTACs Generation and characterisation of potent SHP2 PROTACs; comparison with allosteric inhibitorsRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.